Elanco Animal Health Inc

Over the last four quarters, Elanco Animal Health Inc achieved steady financial progress, growing revenue from $1.03B in Q3 2022 to $1.06B in Q2 2023. Gross profit stayed firm with margins at 59% in Q2 2023 versus 54% in Q3 2022. Operating income totaled $53.00M in Q2 2023, maintaining a 5% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $230.00M. Net income dropped to -$97.00M, with EPS at -$0.20. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.